{"nct_id":"NCT01298141","title":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","status":"COMPLETED","status_verified_date":"2021-05","start_date":"2011-08-10","start_date_type":"ACTUAL","primary_completion_date":"2017-09-25","primary_completion_date_type":"ACTUAL","completion_date":"2017-09-25","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TAK"]}